


Pending Claims

A complete list of all claims under examination is set out below. Please amend claims 11, 16, 31, 32, and 51.

1 - 10. (cancelled).

11. (Currently amended) A The compound of ~~claim 50~~ of the formula:



wherein

R₁₁ is C₅-C₁₈ alkyl, C₅-C₁₈ alkenyl, C₅-C₁₈ alkynyl, C₅-C₁₈ alkoxy, C₁-C₁₀ alkyl(C₅-C₆ aryl)R₂₀, C₁-C₁₀ alkyl(C₅-C₆ heteroaryl)R₂₀, C₁-C₁₀ alkyl(C₅-C₆ cycloalkyl)R₂₀, C₁-C₁₀ alkoxy(C₅-C₆ aryl)R₂₀, C₁-C₁₀ alkoxy(C₅-C₆ heteroaryl)R₂₀ or C₁-C₁₀ alkoxy(C₅-C₆ cycloalkyl)R₂₀;

wherein R₂₀ is H or C₁-C₁₀ alkyl;

p and q are integers independently ranging from 1 to 10;

R₂₉ is H, halo, C₁-C₁₂ alkyl, C₂₄-C₁₂ alkenyl, C₂₄-C₁₂ alkynyl, or C₁-C₁₂ alkoxy;

R₇ and R₈ are independently is O, S, or NR₂₆, or N;


R₈ is O, S, or NR₂₆;

wherein R₂₆ is H, F or C₁-C₄ alkyl;

R₂₅ is CH;

R₃ is hydrogen, C₁-C₄ alkyl, (C₁-C₄ alkyl)OH, or (C₁-C₄ alkyl)NH₂;


R₁₅ is



wherein R_{12} is O or S;

X is O, S, CH_2 , $CHOH$, CHF , CF_2 , or $-\overset{\overset{O}{\parallel}}{C}-$;

R_{30} and R_{31} are each independently C_1 - C_2 alkoxy,



R_{23} is H, F, OH, C_1 - C_4 alkyl, CO_2H or $(C_1$ - C_4 alkyl)OH;

R_{24} is H, F, C_1 - C_4 alkyl or PO_3H_2 ; or

R_{23} together with R_{24} and the carbon to which they are attached form a carbonyl group; and


y and m are integers independently ranging from 0 to 4; or
 a pharmaceutically acceptable salt or tautomer thereof.

12. (previously presented) The compound of claim 11 wherein
 - m is 0;
 - y is 0 or 1;
 - R₂₃ and R₂₄ are independently H or F.

13. (previously presented) The compound of claim 11 wherein R₃ is C₁-C₃ alkyl or (C₁-C₄ alkyl)OH; and
 - R₈ is CH.


14. (previously presented) The compound of claim 12 wherein
 - R₁₁ is C₅-C₁₈ alkyl, C₅-C₁₈ alkenyl, C₅-C₁₈ alkynyl, or C₅-C₁₈ alkoxy and
 - R₂₉ is H, halo or C₁-C₁₂ alkyl; or
 - a pharmaceutically acceptable salt or tautomer thereof.

15. (previously presented) The compound of claim 12 wherein
 - y is 0; and
 - R₁₅ is represented by the structure




wherein X is CH₂, CHOH, CHF, CF₂, or $\begin{array}{c} \text{O} \\ \parallel \\ \text{---C---} \end{array}$.

16. (Currently amended) The compound of claim 11 ~~50~~ of the formula:





wherein R_{11} is C_5 - C_{18} alkyl or C_5 - C_{18} alkenyl; and
 R_8 is N, or S;
 or a pharmaceutically acceptable salt or tautomer thereof.

17. (cancelled)
18. (previously presented) The compound of claim 16 wherein R_{11} is C_5 - C_9 alkyl;
 R_{15} is



wherein X is O, CH_2 or CHF;
 R_{30} and R_{31} are independently






and R_3 is CH_3 .

19. - 21. (cancelled)

22. (previously presented) The compound of claim 51 of the formula:




23. (previously presented) The compound of claim 22 wherein R_3 is $\text{C}_1\text{-C}_4$ alkyl or ($\text{C}_1\text{-C}_4$ alkyl)OH;

R_8 is O, S, or N;

R_{23} is H or F; and

R_{15} is represented by the structure




wherein X is O, CH_2 , CHOH , CHF , CF_2 or -C(=O)- .


24. (previously presented) The compound of claim 53 wherein X is O.

25. (previously presented) The compound of claim 53 wherein X is CH_2 , CHF or CF_2 .

26. (previously presented) The compound of claim 53 wherein R_{30} and R_{31} are the same and are




27. (original) The compound of claim 25 wherein R_8 is N.
28. (previously presented) The compound of claim 25 of the formula:



wherein R_{11} is H, C₅-C₁₈ alkyl, C₅-C₁₈ alkenyl, C₅-C₁₈ alkynyl, or C₅-C₁₈ alkoxy;
 R_3 is CH₃; and
 R_{29} is H, C₁-C₄ alkyl.

29. (previously presented) The compound of claim 28 wherein R_{11} is C₅-C₁₈ alkyl, or C₅-C₁₈ alkenyl; and R_{29} H, or C₁-C₄ alkyl.
30. (previously presented) The compound of claim 28 wherein R_{11} is C₅-C₁₈ alkyl or C₅-C₁₈ alkenyl; and R_{29} is H.

31. (Currently amended) A pharmaceutical composition comprising a compound of the formula:



wherein

R₁₁ is C₅-C₁₈ alkyl, C₅-C₁₈ alkenyl, C₅-C₁₈ alkynyl, C₅-C₁₈ alkoxy, C₁-C₁₀ alkyl(C₅-C₁₀ aryl)R₂₀, C₁-C₁₀ alkyl(C₅-C₁₀ heteroaryl)R₂₀, C₁-C₁₀ alkyl(C₅-C₁₀ cycloalkyl)R₂₀, C₁-C₁₀ alkoxy(C₅-C₁₀ aryl)R₂₀, C₁-C₁₀ alkoxy(C₅-C₁₀ heteroaryl)R₂₀ or C₁-C₁₀ alkoxy(C₅-C₁₀ cycloalkyl)R₂₀;

wherein R₂₀ is H or C₁-C₁₀ alkyl;

R₂₉ is H, halo, C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, or C₁-C₁₂ alkoxy;

R₃ is H, C₁-C₆ alkyl, (C₁-C₄ alkyl)OH, or (C₁-C₄ alkyl)NH₂;

R₂₃ is H, F, CO₂H, OH, C₁-C₆ alkyl, C₁-C₄ alkyl, or (C₁-C₄ alkyl)OH, or (C₁-C₄ alkyl)NH₂;

R₂₄ is H, F, C₁-C₄ alkyl or PO₃H₂; or

R₂₃ together with R₂₄ and the carbon to which they are attached form a carbonyl group;

R₇ and R₈ are independently is O, S, or NR₂₆, or N;


R₈ is O, S, or NR₂₆;

wherein R₂₆ is H, F or C₁-C₄ alkyl;

R₂₅ is CH or CR₂₆;

wherein R₂₆ is H, F or C₁-C₄ alkyl;


R₁₅ is



wherein R_{12} is O, NH or S;

X is O, NH, S, CH_2 , CHOH, CHF, CF_2 , or $-\text{C}(=\text{O})-$; and

each R_{30} is independently and each R_{31} is independently C_1 - C_2 alkoxy,




y and m are integers independently ranging from 0 to 4;

p and q are integers independently ranging from 1 to 10;

a pharmaceutically acceptable salt or tautomer thereof;

and a pharmaceutically acceptable carrier.

32. (currently amended) The composition of claim 31 comprising a compound of the formula:



wherein R_{11} is C_5 - C_{18} alkyl, C_5 - C_{18} alkenyl, C_5 - C_{18} alkynyl, or C_5 - C_{18} alkoxy;

wherein p and q are integers independently ranging from 1 to 10;

Q is



wherein R_7 and R_8 are independently O , S , or NR_{26} or N ;

R_8 is O , S , or NR_{26} ;

wherein R_{26} is H , F or C_1 - C_4 alkyl;


R_{25} is CH or CR_{26} ; and

R_{26} is H , F or C_1 - C_4 alkyl;

R_3 is H , C_1 - C_4 alkyl or $(C_1$ - C_4 alkyl) OH ;

R_{23} is H , F or C_1 - C_4 alkyl; and


R_{15} is represented by the structure



wherein R_{12} is O or S ;


X is O , S , CH_2 , $CHOH$, CHF , CF_2 , or $-C(=O)-$;

R_{30} and R_{31} are independently C_1 - C_2 alkoxy,



or a pharmaceutically acceptable salt or tautomer thereof; and
 a pharmaceutically acceptable carrier.

33. (previously presented) The composition of claim 32 wherein R_{23} is H or F; and R_{15} is




wherein X is O, CH_2 , CHOH , CHF , CF_2 , or —C— .

34. (cancelled).

35. (previously presented) The composition of claim 54 wherein

X is CH_2 , CF_2 or CHF ; and


R_{30} and R_{31} are independently $\text{C}_1\text{—C}_2$ alkoxy,




36. - 49. (cancelled)

50. (cancelled)


51. (Currently amended) The compound of claim 11 ~~50~~ of the formula



wherein R_{11} is C_5 - C_{18} alkyl, C_5 - C_{18} alkenyl, C_5 - C_{18} alkynyl, or C_5 - C_{18} alkoxy;
 R_{15} is



wherein X is O , CH_2 , $CHOH$, CHF , CF_2 , or $\text{---}\overset{\overset{O}{\parallel}}{C}\text{---}$;
 R_{30} and R_{31} are independently C_1 - C_2 alkoxy,




Q is



R_{23} is H or F.


52. (previously presented) The compound of claim 51 of the formula:



R_{12} is O; and X is O, CH_2 , $CHOH$, CHF , CF_2 , and $\overset{\overset{O}{\parallel}}{C}-$.

53. (previously presented) The compound of claim 23 wherein X is O, CH_2 , CHF or CF_2 .

54. (previously presented) The composition of claim 33 wherein Q is



55. (previously presented) The composition of claim 35 wherein Q is

